IP Library Granted Patent US 8,840,916
Granted Patent B2
US 8,840,916 · App. 13/900,338 · Granted Sep 23, 2014

Sustained release polymer

Inventor: Richard L. Dunn (Fort Collins, CO)
Assignee: Tolmar Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,840,916
App. No.
13/900,338
Granted
Sep 23, 2014
Kind
B2
Abstract

A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.

Claims (17)

1. A polymer of Formula (I/II):

wherein:

wherein L/G signifies a PLG copolymer segment, the H atoms at both distal ends signify the hydrogen atoms borne by the terminal hydroxyl groups, and R a is an alkylene diradical;

R b and R c are either hydrogen or methyl;

the polymer is substantially insoluble in water and body fluid,

the polymer has substantially no titratable carboxylic acid groups, the polymer has a weight average molecular weight from about 10 kD to about 50 kD, and the polymer in neat form is a solid at ambient temperature.

2. The polymer of claim 1 wherein L/G comprises a lactide/glycolide copolymer segment with a lactide/glycolide ratio of about 45/55 to about 99/1.

3. The polymer of claim 1 wherein L/G comprises a lactide/glycolide copolymer segment with a lactide/glycolide ratio of about 70/30 to about 90/10.

4. The polymer of claim 1 having a weight average molecular weight of about 8 kD to about 100 kD.

5. The polymer of claim 4 having a weight average molecular weight of about 10 kD to about 50 kD.

6. The polymer of claim 4 having a weight average molecular weight of about 15 kD to about 45 kD.

7. The polymer of claim 4 wherein R a is a linear unsubstituted carbon chain.

8. The polymer of claim 7 wherein R a is a linear unsubstituted carbon chain of 6 carbon atoms.

9. The polymer of claim 4 wherein a polydispersity of the polymer is about 1.2 to about 2.0.

10. The polymer of claim 4 wherein a polydispersity of the polymer is about 1.4 to about 1.7.

11. The polymer of claim 4 wherein an inherent viscosity of the polymer is about 0.20 dL/gm to about 0.60 dL/gm.

12. The polymer of claim 4 wherein an inherent viscosity of the polymer is about 0.25 dL/gm to about 0.40 dL/gm.

Assignments (3)
SECURITY INTEREST Recorded Oct 2, 2017
From: TOLMAR THERAPEUTICS, INC.; TOLMAR, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 043756/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: DUNN, RICHARD L.
To: QLT USA, INC.
Reel/Frame 040637/0985 →
CHANGE OF NAME Recorded Dec 15, 2016
From: QLT USA, INC.
To: TOLMAR THERAPEUTICS, INC.
Reel/Frame 040979/0184 →
Continuity (5)
Continuation 11469392 · Aug 31, 2006
Continuation In Part 10872671 · Jun 21, 2004
Continuation 10373400 · Feb 24, 2003
Continuation 09711758 · Nov 13, 2000
Related Publication 20130303722A1 · Nov 14, 2013